UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported)

July 27, 201 7

 

 

Pulse Biosciences , Inc.

(Exact name of registrant as specified in its charter)

 

 

 



 

 

 

 



 

 

 

 



 

 

 

 

 Nevada

 

001-37744

 

46-5696597

(State or other jurisdiction

of incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

3957 Point Eden Way

Hayward , California 94 545

(Address of principal executive offices, including zip code)

( 510 )   906-4600

(Registrant’s telephone number, including area code)

(Former name or former address, if changed since last report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2):





 

 

 



☐

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)



☐

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)



☐

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))



☐

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

   



  Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒  

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.                    ☒  

 

 





 





ITEM 2.02.   RESULTS OF OPERATIONS AND FINANCIAL CONDITION.

On July 27 , 201 7 ,   Pulse Biosciences , Inc. announced its financial results for the fiscal quarter ended June 30, 2017 . A copy of the press release containing the announcement is included as Exhibit 99.1 and is incorporated herein by reference.

This information, as well as Exhibit 99.1, is intended to be furnished under Item 2.02 of Form 8-K, “Results of Operations and Financial Condition” and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), nor incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.



ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS





 

 

(d)

 

Exhibits.



 

 

 Exhibit No.

 

Description

99.1

 

Press Release issued by Pulse Biosciences, Inc. dated July 27, 2017



 

 







 

 





SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 



 

 



 

 



 

 

Pulse Biosciences, Inc.



 

By:

 

/s/ Brian B. Dow         



 

Brian B. Dows

Chief Financial Officer, Senior Vice President , Secretary and Treasurer  

(Principal Financial and Principal Accounting Officer )



Date: July 27 , 201 7

 





 

EXHIBIT INDEX



ch

 

 



 

 

 Exhibit   No.

 

Description

99.1

 

Press Release issued by Pulse Biosciences, Inc. dated July   27 , 2017





Pulse Biosciences (NASDAQ:PLSE)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Pulse Biosciences Charts.
Pulse Biosciences (NASDAQ:PLSE)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Pulse Biosciences Charts.